The experimental electrode device tests for interleukin-6, a biomarker of sepsis, in blood samples. The device can also detect what type of infection a patient has and recommend the most appropriate antibiotic treatment.
“The implications for this are massive, and the ability to give the right antibiotic at the right time to the right patient is extraordinary,” study author Dr. David Alcorn of the Royal Alexandra Hospital in Scotland told CNN.
Researchers have applied for research funding and plan to conduct clinical trials of the device, which costs $26 to produce.
More articles on clinical leadership and infection control:
ANA on nurse’s reckless homicide charge: Criminalizing medical errors may deter future reporting
1-in-5 C. diff patients are readmitted to the hospital within 30 days, study finds
Medical board considers further action against former Mount Carmel physician in patient deaths investigation
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.